UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 1312, ~~2024~~2025

HEALTH DISCOVERY CORPORATION

(Exact name of registrant as specified in charter)

333-62216

74-3002154

(State of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

2002 SUMMIT BLVD, SUITE 300
ATLANTA, GA		30319
(Address of principal executive offices)		(Zip Code)

(404) 566-4865

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act.

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

☐ Pre-commencement communications pursuant to Rule 14d–2(b) under the Exchange Act.

☐ Pre-commencement communications pursuant to Rule 13e–4(c) under the Exchange Act.

Securities registered pursuant to Section 12(g) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, no par value	HDVY	N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 87.01 ~~Other~~Regulation ~~Events~~FD Disclosure

On September 1312, ~~2024~~2025, ~~the United States District Court for the Northern District of Georgia granted~~ Health Discovery Corporation~~’s (“HDC”~~ orissued the “Company”) motion for summary judgment in full and entered judgment in favor of all defendants on all counts in the shareholder derivative lawsuit brought by Vennwest Global Technologies, Inc. (“Vennwest”). The Vennwest lawsuit, which was initially filed in September 2020, alleged misconduct by the Company and its board of directors (“Board”) in connection with approving a ~~series~~letter ~~of loans~~ to ~~HDC~~its ~~by certain directors and~~ shareholders ofproviding ~~HDC.~~an ~~The~~update Vennwest lawsuit contains virtually identical claims against HDC that shareholders William Quirk and Cindy Bear had alleged, which lawsuit was also dismissed. The loans at issue were sought by the Company to ~~allow it to meet its financial obligations in connection with litigation that was ongoing at~~ the ~~time. The District Court found that the loans were presented to and approved by the Board, in all respects, in compliance with Georgia~~Company’s ~~conflicting~~ ~~interest~~recent ~~transaction statutes~~activity, ~~requiring~~a ~~the~~copy ~~dismissal~~ of ~~all~~which ~~claims~~is ~~asserted~~furnished byherewith as ~~the~~Exhibit ~~plaintiff~~99.1 ~~The~~to ~~judgment~~this ~~affords~~Current ~~HDC~~Report ~~the recovery~~on ofForm ~~its~~8-K ~~costs~~and ~~associated~~is ~~with~~incorporated ~~the~~by ~~lawsuit~~reference ~~(which~~into ~~does~~this ~~not~~Item ~~include~~7.01 ~~the~~by ~~recovery of its legal fees)~~reference.

~~The~~In ~~Court’s~~accordance ~~order~~with ~~and~~General Instruction B.2 ~~judgment~~of ~~represent~~Form a8-K, ~~complete~~the ~~refutation~~information in this Item 7.01 of ~~these~~this ~~baseless~~Current ~~claims~~Report on Form 8-K, including the information set forth in Exhibit 99.1, is being furnished and ashall ~~total~~not ~~vindication~~be deemed “filed” for purposes of Section 18 of the ~~Company’s~~Exchange ~~longstanding~~Act, ~~position that~~nor ~~these~~shall ~~claims~~it ~~were~~be ~~entirely~~deemed incorporated ~~without~~by ~~merit~~reference ~~and~~in ~~served~~any ~~only~~filing tounder ~~distract~~the Securities Act or the ~~Company~~Exchange ~~and~~Act, ~~deplete~~except ~~its~~as ~~resources~~shall tobe ~~the~~expressly ~~detriment~~set offorth ~~its~~by specific ~~shareholders~~reference in such a filing.

~~Board~~Item ~~member Colleen Hutchinson stated: “We are gratified by the decision of the Court in this matter~~9.01 ~~Now~~Financial ~~that~~Statements ~~this matter has been resolved, the Board looks forward to focusing on the development of the Company’s technology without the unnecessary distraction~~ and ~~cost that this lawsuit has caused over the previous four years.”~~Exhibits

2(d) Exhibits

~~SIGNATURES~~99.1 Letter to Shareholders

~~Pursuant~~104 Cover toPage ~~the~~Interactive ~~requirements of~~Data ~~the~~File ~~Securities~~(embedded ~~Exchange~~within ~~Act of 1934,~~ the ~~registrant~~Inline ~~has~~XBRL ~~duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.~~document)

	HEALTH DISCOVERY CORPORATION
	Registrant
Dated: September 18, 2024	By:	/s/ Colleen Hutchinson
		Colleen Hutchinson Board Member

3SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	HEALTH DISCOVERY CORPORATION
	Registrant

Dated: September 12, 2025	By:	/s/ Alan K. Hauser
		Alan K. Hauser Chief Executive Officer

Filing Compare · HEALTH DISCOVERY CORP